Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTengine IMA203-101
2024-515114-41-00Phase 2Authorised
- Sponsor
- Immatics
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label trial of anzutresgene autoleucel, IMA203CD8 and nivolumab in Nonhematologic neoplasms (4 arms), sponsored by Immatics. Primary endpoints: Treatment-emergent adverse events (TEAEs), Adverse events of special interest (AESIs) and 3 more. Planned start Aug 2024; status: authorised.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-515114-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515114-41-00.